Emblem Corp Share Price

Stocks

EMC

CA29082J1084

Pharmaceuticals

End-of-day quote Toronto S.E. 01:29:45 19/03/2019 am IST 5-day change 1st Jan Change
1.880 CAD +1.62% Intraday chart for Emblem Corp +1.62% +106.59%

Valuation: Emblem Corp

Market Cap 25Cr 22Cr 20Cr 18Cr 35Cr 2.36TCr 35Cr 237.02Cr 93Cr 1.18TCr 93Cr 91Cr 3.91TCr P/E 2017
-16.3x
P/E 2018 -4.48x
Enterprise Value 22Cr 19Cr 18Cr 16Cr 31Cr 2.09TCr 31Cr 209.29Cr 82Cr 1.04TCr 82Cr 81Cr 3.45TCr EV / Sales 2017
7,23,52,077x
EV / Sales 2018 1,09,15,686x
Free-Float
98.36%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer - -
Chief Executive Officer - 01/12/2017
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 44 -
Director/Board Member - 06/11/2018
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.62%+1.62% - - 0
-1.13%+1.13%-8.15%-3.96% 1.38TCr
-1.30%+1.34%-29.93%-50.51% 530.03Cr
-1.44%+5.41%+5.61%+9.42% 523.32Cr
+0.42%+0.30%+2.69%-31.78% 413.47Cr
-0.11%+2.24%-2.45%-2.80% 374.79Cr
-1.75%-2.12%-2.55%+5.14% 366.29Cr
-0.31%-0.44%-4.86%+15.27% 351.59Cr
-1.00%-0.69%-14.04%-22.43% 249.12Cr
-1.17%+2.19%-2.73%+51.63% 192.47Cr
Average -0.62%-0.09%-6.27%-3.34% 438.2Cr
Weighted average by Cap. -0.93%-0.23%-7.00%-6.82%

Financials

2017 2018
Net sales 2.69 2.34 2.18 2 3.79 256.26 3.83 25.71 10.05 128.1 10.12 9.9 424.45 8.22 7.14 6.66 6.12 11.57 782.19 11.69 78.49 30.68 391.01 30.88 30.2 1.3T
Net income -1.21Cr -1.05Cr -97.97L -90L -1.7Cr -115.11Cr -1.72Cr -12Cr -4.52Cr -58Cr -4.54Cr -4.44Cr -190.66Cr -2.43Cr -2.11Cr -1.96Cr -1.8Cr -3.41Cr -230.76Cr -3.45Cr -23Cr -9.05Cr -115.35Cr -9.11Cr -8.91Cr -382.21Cr
Net Debt -2.15Cr -1.87Cr -1.74Cr -1.6Cr -3.03Cr -204.63Cr -3.06Cr -21Cr -8.03Cr -102.29Cr -8.08Cr -7.9Cr -338.93Cr -2.91Cr -2.52Cr -2.35Cr -2.16Cr -4.09Cr -276.36Cr -4.13Cr -28Cr -11Cr -138.15Cr -11Cr -11Cr -457.74Cr
Logo Emblem Corp
Emblem Corp is a Canada-based Company engaged in alternative medicine sector. The Company is producer and distributor of medical cannabis and cannabis derivatives licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates in one segment, the production and sale of medical cannabis to patients who have received medical authorizations to acquire and use cannabis. The Company offers fully integrated services covering the full cannabis spectrum, from growing to selling, as well as educating and also creating new forms of cannabinoid-based medication in standardized dosages. All of the Company’s assets are located in Canada.
Employees
-